Lung Cancer Mutation Panel (EGFR, KRAS, ALK)
Also known as: Non-Small Cell Lung Cancer (NSCLC)
Use
This panel is comprised of mutational analysis of the EGFR and KRAS genes and assessment for ALK locus rearrangement using an FDA‑cleared FISH assay. These are the most common tumor‑associated genetic changes in non‑small cell lung cancer (NSCLC) and help guide therapy. Patients with EGFR mutations are generally responsive to EGFR‑directed kinase inhibitors, whereas those with ALK gene rearrangements are candidates for treatment with the ALK inhibitor crizotinib. The presence of KRAS mutation in lung adenocarcinoma predicts non‑response to kinase inhibitors and poorer outcomes.
Special Instructions
Not provided.
Limitations
Not provided.
Methodology
NGS
Biomarkers
Result Turnaround Time
Not provided.
Related Documents
For more information, please review the documents below
Specimen
Tissue (FFPE)
Volume
Not provided
Minimum Volume
8 unstained charged (+) slides
Storage Instructions
Room temperature; Refrigerated acceptable; Frozen unacceptable
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 5 years |
| Refrigerated | 5 years |
Other tests from different labs that may be relevant